ASRT

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Q4 Financial Performance: Assertio Holdings reported a Q4 Non-GAAP EPS of -$0.03, missing expectations by $0.04, while revenue was $32.1 million, beating estimates by $3.43 million.

2025 Financial Guidance: The company provided initial guidance for 2025, projecting net product sales between $108.0 million and $123.0 million, and adjusted EBITDA ranging from $10.0 million to $19.0 million.

Earnings Release Announcement: Assertio Holdings, Inc. will release its fourth quarter and full year 2024 financial results on March 12, 2025, after market close, followed by a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Company Overview: Assertio is a pharmaceutical company focused on marketing differentiated products for oncology, neurology, and pain management, aiming to address patients' needs.

Class Action Lawsuit Filed: A class action lawsuit has been initiated against Assertio Holdings, Inc. and its executives for alleged violations of federal securities laws related to the merger with Spectrum Pharmaceuticals, claiming misleading statements in the Registration Statement regarding the business prospects and risks associated with the merger.

Stock Price Decline: Following disappointing financial results and the loss of exclusivity for Indocin, Assertio's stock price plummeted by 43.2% after the announcement, reflecting an overall decline of approximately 82% since the merger date.

Clinical Trial Results: Assertio Holdings announced positive results from a clinical trial of Rolvedon (eflapegrastim-xnst) for early stage breast cancer patients, showing effective neutrophil recovery and low rates of febrile neutropenia when administered the same day as chemotherapy.

Company Commitment: Assertio's CEO emphasized the company's dedication to improving patient outcomes through innovative treatment options, highlighting the encouraging safety and efficacy profile of Rolvedon demonstrated in the trial.

Leadership Changes at Assertio Holdings: Assertio Holdings has established a new Transformation Office, appointing Paul Schwichtenberg as Chief Transformation Officer and Mary Pietryga as Chief Commercial Officer effective December 16, 2024.

Company Performance: Assertio reported a non-GAAP EPS of $0.03 and revenue of $228.7 million for Q3 2024, significantly exceeding expectations by $199.83 million.

Beam Therapeutics Leadership Change: Beam Therapeutics has appointed Sravan K. Emany as CFO, effective December 19, 2024; he previously held the same position at Ironwood Pharmaceuticals.

Assertio Holdings Financial Performance: Assertio Holdings reported a Q3 2024 Non-GAAP EPS of $0.03 and revenue of $228.7 million, significantly exceeding expectations by $199.83 million, while its stock saw a premarket decline of 3%.

New CFO Appointment: Beam Therapeutics has appointed Sravan K. Emany as the new chief financial officer, effective December 19, 2024, bringing extensive experience from his previous roles in multinational corporations and financial institutions.

Company's Mission and Future Plans: Mr. Emany expressed enthusiasm for Beam's mission to transform genetic disease treatment through precision medicines, highlighting the company's strong financial foundation and potential for significant advancements in its clinical pipeline.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Investigation Request: The Buxton Helmsley Group (BHG) has called for a Senate investigation into alleged clinical data fraud related to Assertio Holdings' cancer treatment, Rolvedon, following the abrupt resignations of key board members.

Concerns Over Patient Safety: BHG emphasizes the need for transparency and accountability regarding the integrity of clinical data submissions to the FDA, citing potential risks to patient health and public safety.

Conference Call Overview: Assertio Holdings, Inc. held a Q3 2024 earnings conference call on November 11, 2024, featuring CEO Brendan O'Grady and CFO Ajay Patel, discussing the company's financial results and business outlook.

Forward-Looking Statements: The management emphasized that projections made during the call involve risks and uncertainties, which are detailed in their press release and SEC filings.

Allegations of Fraud: The Buxton Helmsley Group (BHG) has accused Assertio Holdings of product-related fraud linked to its acquisition of Spectrum Pharmaceuticals, citing evidence such as requests to delete adverse event data and discrepancies in clinical trial reports.

Call for Transparency: BHG is urging Assertio's board to release the full investigation report regarding these allegations and communicate with whistleblowers, while also indicating plans to engage with the U.S. SEC on the matter.

Earnings Reports Overview: Several companies, including Grab Holdings Limited, IAC Inc., and DoubleDown Interactive Co., are set to report their earnings for the quarter ending September 30, 2024, with varying forecasts and previous year comparisons indicating significant changes in performance.

Performance Trends: Most companies are showing a decline in earnings per share compared to the same quarter last year, while a few, like DoubleDown Interactive Co. and James River Group Holdings, are experiencing slight increases.

Response to Allegations: Assertio Holdings, Inc. refuted baseless claims made by short-seller Alex Parker regarding the safety of Rolvedon and the company's accounting practices, asserting that these allegations have been thoroughly investigated and found to be false.

Legal Action Consideration: The company is contemplating legal and regulatory actions against Parker for his repeated unfounded accusations and attempts to extract financial benefits from Assertio.

Fraud Allegations Against Assertio: The Buxton Helmsley Group (BHG) has raised serious concerns about product-related fraud linked to Assertio's acquisition of Spectrum Pharmaceuticals' Rolvedon, alleging that the Assertio board ignored whistleblower reports and engaged in misconduct.

Investment Position Change: BHG has shifted from a long equity position to a short position in Assertio, warning stockholders to conduct due diligence and consider divesting their shares due to potential insolvency and ongoing fraud issues.

Company Announcement: Assertio Holdings, Inc. will have CEO Brendan O'Grady participate in a fireside chat at the Maxim Group 2024 Healthcare Virtual Summit on October 15, 2024, at 1:00 pm Eastern Time.

About Assertio: Assertio is a pharmaceutical company focused on offering differentiated products through comprehensive commercial capabilities, including marketing and market access strategies.

Quarterly Performance: Assertio reported a quarterly loss of $0.04 per share, missing the Zacks Consensus Estimate of a loss of $0.02, while revenues were $31.13 million, surpassing estimates by 2.51%. The company has shown mixed earnings outlooks with a current Zacks Rank of #3 (Hold).

Industry Context and Future Outlook: Assertio's stock has gained about 16.8% this year, outperforming the S&P 500, but future performance will depend on management's commentary and industry trends, as well as upcoming earnings reports from peers like Esperion Therapeutics.